This year's meeting will focus on forging new solutions for economic, health, climate, and humanitarian issues.

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Gilead Sciences’ (NASDAQ: GILD) Q2 earnings are scheduled to be released on August 7, after market close. The pharma company ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Among its other ratings, Gilead's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over ...

How Gilead is helping innovate HIV prevention, removing stigma and empowering Black women. By Spenser Mestel This story was created in paid partnership with Gilead Sciences. Pre-exposure ...

Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.